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Results: Differential gene expression analysis allowed delineation of a 150-
gene signature representative for high ALK activity in NB. This signature was 
significantly enriched for genes implicated in MAPK/ERK signaling, including 
several negative MAPK regulators, indicating strong ALK induced MAPK activity. 
In addition, genes implicated in neuronal differentiation and growth control 
were identified. We selected ETV5, known to be involved in neuronal fate 
decision and metastasis/invasion, for further investigation. RNAi-mediated ETV5 
knock down showed drastic reduction in cellular growth measured in NB cells 
with activated ALK. Elevated ETV5 levels were apparent in human and mouse 
ALK positive NB. Remarkably, inhibition of ALK signaling in NPM/ALK positive 
lymphoma and EML4/ALK positive lung cancer also strongly reduced ETV5 
expression. 
Conclusion: We obtained for the first time a detailed picture of the 
transcriptional consequences of sustained ALK signaling in human and mouse 
NB cells. The MAPK driven ETV5 oncogene was identified as a robustly 
regulated ALK target in NB and other ALK activated cancers, thus offering new 
therapeutic targets for molecular therapy.
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Background: We previously found that the growth factor midkine (MK) is 
highly expressed in human neuroblastoma (NB), and its blood levels work as a 
prognosis factor (Ikematsu et al., Cancer Sci 99, 2008; Br J Cancer 88, 2003). 
The purpose of this research is to search for active antitumor ingredients from 
marine resources, using MK expressed by NB cells as an indicator.
Methods: We used a library of 700 ingredients of marine resources extracted 
from the sea near Okinawa, Japan. First, ingredients of the library were added 
to SK-N-SH cells, a NB cell line. The culture supernatants of both 24 h and 
48 h after sample addition were collected. Next, the amounts of MK in the 
culture supernatants were measured by MK-ELISA, which we had developed. 
Ingredients which showed the reduction in MK production was applied to the 
2nd screening. In the 2nd screening, MK production as well as cell viability was 
evaluated.
Results: We obtained 71 candidates of 700 after the 1st screening. Among 
71 candidates, 8 ingredients exhibited the reduction of MK production and 
cell viability in the 2nd screening. These ingredients were derived from marine 
resources classified into sponges, echinoderm, and cnidarian.
Conclusions: The ingredients with antitumor activity could be seeds for 
developing therapeutics for NB.
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Background: Activating mutations of the anaplastic lymphoma receptor 
tyrosine kinase gene (ALK) were identified in both somatic and familial 
neuroblastoma. The most common somatic mutation, F1174L, is associated with 
NMYC amplification and displayed an efficient transforming activity in vivo. In 
addition, both AKL-F1174L and NMYC were shown cooperate in neuroblastoma 
tumorigenesis in animal models. To analyse the role of ALK mutations in 
the oncogenesis of neuroblastoma, ALK wt and various ALK mutants were 
transduced in murine neural crest stem cells (MONC1).
Methods: ALK-wt, and F1174L, and R1275Q mutants were stably expressed 
by retroviral infection using the pMIGR1 vector in the murine neural crest stem 
cell line MONC-1, previously immortalised with v-myc, and further implanted 
subcutaneously or orthotopically in nude mice.
Results: Both MONC1-ALK-F1174L and -R1275Q cells displayed a rapid 
tumour forming capacity upon subcutaneous injection in nude mice compared to 
control MONC1-MIGR or MONC1 cells. Interestingly, the transforming capacity 
of the F1174L mutant was much more potent compared to that of R1275Q 
mutant in murine neural crest stem cells, while ALK-wt was not tumorigenic. In 
addition, mice implanted orthotopically in the left adrenal gland with MONC1-
ALK-F1174L cells developed highly aggressive tumours in 100% of mice within 
three weeks, while MONC1-Migr or MONC1 derived tumours displayed a 
longer latency and a reduced tumour take. 
Conclusions: The activating ALK-F1174L mutant is highly tumorigenic in neural 
crest stem cells. Nevertheless, we cannot exclude a functional implication of 
the v-myc oncogene used for MONC1 cells immortalisation. Indeed, the control 
MONC1-Migr and MONC1 cells were also able to derive subcutaneous and 
orthotopic tumours, although with considerable reduced efficiency. Further 
investigations using neural crest stem cell lacking exogenous myc expression 
are currently on way to assess the exclusive role of ALK mutations in NB 
oncogenesis.
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Background: Activating ALK mutations are present in almost 10% of primary 
neuroblastomas (NB) and serve as new therapeutic targets for treatment. Clinical 
trials for small molecule ALK inhibitors have been initiated for NB and other ALK 
driven tumor entities. However, in many instances, tumors acquire resistance to 
small molecule inhibitors, illustrating the need for additional compounds directed 
against downstream target genes or alternative survival pathways. To achieve 
this goal, we analyzed aberrant ALK signaling to identify such vulnerable nodes 
for combined pharmacological targeting. 
Methods: Transcriptome profiling was performed on 10 NB cell lines (ALK wild 
type, ALKF1174L, ALKR1275Q mutant or amplified) following NVP-TAE684 
treatment. Data mining analysis and functional validation experiments were 
integrated to identify ALK driven functional cellular networks and aberrantly 
regulated downstream pathway components.
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